OpenAlex
PricingAboutJobs
Log inGet started
Work

CML-277: Efficacy of Bosutinib in Imatinib-Resistant vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

HTML

Year: 2020
Type: conference-abstract
Source: Clinical Lymphoma Myeloma & Leukemia
DOI: 10.1016/s2152-2650(20)30826-0
Authors: B Douglas Smith, Gianantonio Rosti, Tim Brümmendorf, Gail Roboz, Carlo Gambacorti-Passerini, Aude Charbonnier, Andrea Viqueira, Eric Leip, Frank Giles, Thomas Ernst, Frank Castagnetti, Andreas Hochhaus
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Bologna, Universitätsklinikum Aachen, RWTH Aachen University, Weill Cornell Medicine, University of Milano-Bicocca, Institut Paoli-Calmettes, Pfizer (Spain), Pfizer (United States), Jena University Hospital
Language: English

Topic: Chronic Myeloid Leukemia Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: bosutinib, chronic myeloid leukemia, chronic phase, imatinib resistance, dasatinib resistance, nilotinib resistance, tyrosine kinase inhibitor intolerance, complete cytogenetic response, complete molecular response, treatment discontinuation, adverse events, Philadelphia chromosome-positive leukemia, long-term follow-up, dose intensity, treatment duration, progression-free survival
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2985522202
Cites:
Cited by: 2
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security